错误部

The Lancet Pub Date : 2024-11-14 DOI:10.1016/s0140-6736(24)02478-4

{"title":"错误部","authors":"","doi":"10.1016/s0140-6736(24)02478-4","DOIUrl":null,"url":null,"abstract":"Park S-J, Ahn J-M, Kang D-Y, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet 2024; 403: 1753–65—In table 2 of this Article, the proportion of patients in the optimal medical therapy group with target-vessel-related myocardial infarction at 4 years should have been 0·9%. This correction has been made to the online version as of Nov 14, 2024.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Department of Error\",\"authors\":\"\",\"doi\":\"10.1016/s0140-6736(24)02478-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Park S-J, Ahn J-M, Kang D-Y, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet 2024; 403: 1753–65—In table 2 of this Article, the proportion of patients in the optimal medical therapy group with target-vessel-related myocardial infarction at 4 years should have been 0·9%. This correction has been made to the online version as of Nov 14, 2024.\",\"PeriodicalId\":22898,\"journal\":{\"name\":\"The Lancet\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s0140-6736(24)02478-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0140-6736(24)02478-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Park S-J、Ahn J-M、Kang D-Y等：预防性经皮冠状动脉介入治疗与单纯最佳药物治疗治疗易损冠状动脉粥样硬化斑块（PREVENT）：一项多中心、开放标签、随机对照试验。Lancet 2024; 403: 1753-65-在本文表2中，最佳药物治疗组中4年后发生靶血管相关心肌梗死的患者比例应为0-9%。截至2024年11月14日的在线版本已作此更正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Department of Error

Park S-J, Ahn J-M, Kang D-Y, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet 2024; 403: 1753–65—In table 2 of this Article, the proportion of patients in the optimal medical therapy group with target-vessel-related myocardial infarction at 4 years should have been 0·9%. This correction has been made to the online version as of Nov 14, 2024.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Lancet

自引率

0.00%

发文量